Last updated: July 16, 2026
Meda Pharmaceuticals Inc. sued Amneal Pharmaceuticals LLC in a Hatch-Waxman-related patent infringement action in case 1:15-cv-00617. The record indicates a disputes centered on FDA Paragraph IV-type generic entry risk for Meda’s branded product. The available docket information is insufficient to produce a complete, accurate claim-by-claim infringement and invalidity analysis, including asserted patents, specific claims, dispositive rulings, settlement terms, and the final judgment posture.
What does Meda v. Amneal Pharmaceuticals LLC (1:15-cv-00617) litigate?
Answer: A Hatch-Waxman patent infringement case tied to a generic “enter at risk” challenge, brought by Meda against Amneal.
Which product and active ingredient are involved?
Answer: Not determinable from the information provided.
Is this Paragraph IV litigation tied to an ANDA?
Answer: The case style and typical structure of these disputes indicate it is consistent with an ANDA/Paragraph IV framework, but the specific ANDA, listed patents, and FDA submission identifiers are not provided.
Which patents were asserted in Meda v. Amneal (1:15-cv-00617)?
Answer: Not determinable from the information provided.
What is the asserted patent list?
Answer: Not available in the provided dataset.
What is the technology coverage?
Answer: Not available (formulation, polymorph, method-of-use, process, or kit claims cannot be confirmed).
What happened procedurally in Meda v. Amneal (1:15-cv-00617)?
Answer: Not determinable from the information provided.
Key procedural milestones (typical set, status not available)
- Complaint and service
- Amneal’s answer and defenses
- Claim construction (Markman) proceedings
- Summary judgment motions
- Bench trial or jury trial schedule (if any)
- Final judgment date
How did the court rule in Meda v. Amneal (1:15-cv-00617)?
Answer: Not determinable from the information provided.
Disposition type
- Judgment on the pleadings
- Summary judgment
- Dismissal
- Voluntary dismissal
- Settlement and stipulation of dismissal
Injunction or final non-infringement/invalidity rulings
Answer: Not available.
Did Meda v. Amneal (1:15-cv-00617) end in settlement?
Answer: Not determinable from the information provided.
Settlement terms that drive generic timing
- Carve-outs, license scope, and permitted launch dates
- Dismissal with prejudice or without prejudice
- Agreement provisions affecting FDA approval timing
- Ongoing covenant-not-to-sue boundaries
What Orange Book status and exclusivity did this litigation target?
Answer: Not determinable from the information provided.
Patents likely at issue (not confirmed)
- Drug substance/active ingredient patents
- Formulation or polymorph patents
- Method-of-use patents
- Manufacturing/process patents
- Pediatric or exclusivity-related extensions
What generic entry risks exist for Amneal if Meda v. Amneal (1:15-cv-00617) concludes adversely?
Answer: Not determinable from the information provided.
Risks typically assessed in this posture
- Remaining unexpired patents on the Orange Book
- Barriers from additional listed patents (continuation filings, terminal disclaimers)
- Impacts from claim construction outcomes
- Risk of injunction or damages exposure
How does this case affect the competitive landscape?
Answer: Not determinable from the information provided.
Practical impacts typically tracked
- Entry timing into the relevant NDC market
- Whether other ANDA filers are delayed by the same patent estate
- Whether Amneal becomes a preferred licensee or launches at risk
Key Takeaways
1. The docket identifier 1:15-cv-00617 matches a Meda v. Amneal patent infringement dispute.
2. The case is consistent with Hatch-Waxman/Paragraph IV-style generic entry litigation.
3. A complete and accurate litigation summary cannot be produced from the provided inputs because the record excerpt does not include asserted patents, product/NDC linkage, procedural milestones, rulings, or disposition/settlement terms.
FAQs
- What court and judge handled Meda v. Amneal (1:15-cv-00617)?
- Which Meda Orange Book patents did Amneal challenge in the ANDA tied to 1:15-cv-00617?
- Did the court issue a Markman order affecting infringement or noninfringement scope?
- Was Amneal’s proposed generic enjoined or permitted to launch during or after 1:15-cv-00617?
- Did Meda and Amneal reach a settlement that set launch dates or licensing terms?
References
- Meda Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC, No. 1:15-cv-00617 (docket).
